Skip to content

Study · In vitro (cells) · 2014

8 results

The rescue of microtubule-dependent traffic recovers mitochondrial function in Parkinson's disease.

Esteves AR, Gozes I, Cardoso SM

Biochimica et biophysica acta11 Oct 2013Cited by 92 (Europe PMC)

PMID24120997 (opens in a new tab)DOI10.1016/j.bbadis.2013.10.003 (opens in a new tab)PepBankPUB-24120997
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In Parkinson's disease cells, NAP improved microtubule-dependent traffic.

    In plain wordsIn lab tests with Parkinson's disease cells, NAP improved transport along microtubules.

    Peptide
    Davunetide
    Outcome
    IncreaseMicrotubule-dependent traffic
    Study

    humann: not reported in source

    Parkinson's disease cells
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In this work we provide new evidence that an agent that promotes microtubule network assembly, NAP (davunetide), improves microtubule-dependent traffic, restores the autophagic flux and potentiates autophagosome-lysosome fusion leading to autophagic vacuole clearance in Parkinson's disease cells.
  2. 02LabIn vitro (cells)Mechanism

    In Parkinson's disease cells, NAP restored autophagic flux.

    In plain wordsIn lab tests with Parkinson's disease cells, NAP restored autophagic flux.

    Peptide
    Davunetide
    Outcome
    IncreaseAutophagic flux
    Study

    humann: not reported in source

    Parkinson's disease cells
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In this work we provide new evidence that an agent that promotes microtubule network assembly, NAP (davunetide), improves microtubule-dependent traffic, restores the autophagic flux and potentiates autophagosome-lysosome fusion leading to autophagic vacuole clearance in Parkinson's disease cells.
  3. 03LabIn vitro (cells)Mechanism

    In Parkinson's disease cells, NAP potentiated autophagosome-lysosome fusion.

    In plain wordsIn lab tests with Parkinson's disease cells, NAP increased fusion of autophagosomes with lysosomes.

    Peptide
    Davunetide
    Outcome
    IncreaseAutophagosome-lysosome fusion
    Study

    humann: not reported in source

    Parkinson's disease cells
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In this work we provide new evidence that an agent that promotes microtubule network assembly, NAP (davunetide), improves microtubule-dependent traffic, restores the autophagic flux and potentiates autophagosome-lysosome fusion leading to autophagic vacuole clearance in Parkinson's disease cells.
  4. 04LabIn vitro (cells)Mechanism

    In Parkinson's disease cells, NAP promoted autophagic vacuole clearance.

    In plain wordsIn lab tests with Parkinson's disease cells, NAP promoted clearance of autophagic vacuoles.

    Peptide
    Davunetide
    Outcome
    IncreaseAutophagic vacuole clearance
    Study

    humann: not reported in source

    Parkinson's disease cells
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In this work we provide new evidence that an agent that promotes microtubule network assembly, NAP (davunetide), improves microtubule-dependent traffic, restores the autophagic flux and potentiates autophagosome-lysosome fusion leading to autophagic vacuole clearance in Parkinson's disease cells.
  5. 05LabIn vitro (cells)Mechanism

    In Parkinson's disease cells, NAP reduced alpha-synuclein oligomer content.

    In plain wordsIn lab tests with Parkinson's disease cells, NAP reduced alpha-synuclein oligomers.

    Peptide
    Davunetide
    Outcome
    DecreaseAlpha-synuclein oligomer content
    Study

    humann: not reported in source

    Parkinson's disease cells
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, NAP is capable of efficiently reducing alpha-synuclein oligomer content and its sequestration by the mitochondria.
  6. 06LabIn vitro (cells)Mechanism

    In Parkinson's disease cells, NAP reduced mitochondrial sequestration of alpha-synuclein oligomers.

    In plain wordsIn lab tests with Parkinson's disease cells, NAP reduced trapping of alpha-synuclein oligomers by mitochondria.

    Peptide
    Davunetide
    Outcome
    DecreaseMitochondrial sequestration of alpha-synuclein oligomers
    Study

    humann: not reported in source

    Parkinson's disease cells
    Outcome group
    Mitochondrial function · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, NAP is capable of efficiently reducing alpha-synuclein oligomer content and its sequestration by the mitochondria.
  7. 07LabIn vitro (cells)Mechanism

    In Parkinson's disease cells, NAP decreased mitochondrial ubiquitination levels.

    In plain wordsIn lab tests with Parkinson's disease cells, NAP decreased mitochondrial ubiquitination.

    Peptide
    Davunetide
    Outcome
    DecreaseMitochondrial ubiquitination
    Study

    humann: not reported in source

    Parkinson's disease cells
    Outcome group
    Mitochondrial function · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Most interestingly, NAP decreases mitochondrial ubiquitination levels, as well as, increases mitochondrial membrane potential indicating a rescue in mitochondrial function.
  8. 08LabIn vitro (cells)Mechanism

    In Parkinson's disease cells, NAP increased mitochondrial membrane potential.

    In plain wordsIn lab tests with Parkinson's disease cells, NAP increased mitochondrial membrane potential.

    Peptide
    Davunetide
    Outcome
    IncreaseMitochondrial membrane potential
    Study

    humann: not reported in source

    Parkinson's disease cells
    Outcome group
    Mitochondrial function · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Most interestingly, NAP decreases mitochondrial ubiquitination levels, as well as, increases mitochondrial membrane potential indicating a rescue in mitochondrial function.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.